Pharma — India Patent Cases
967 decisions indexed
Page 6 of 33 · 967 total
Hamdard National Foundation (India) v.Klm Pharma Seema Aggarwal Proprietor
The plaintiffs, part of the Hamdard Group, sued KLM Pharma for infringing their well-known Unani medicine trademark 'SAFI' and its associated trade dress. The defendant was found to be using a deceptively similar mark, 'SAIFI,' for identical goods (blood purifier).
Novartis Ag v.Alembic Pharmaceuticals Limited
Novartis Ag filed a suit seeking permanent injunction and damages for infringement of its registered Indian patent (IN 283133) related to Ribociclib. The court proceeded with various interlocutory applications, including those regarding discovery and stay, while the defendant submitted that it is only engaged in permissible research and development.
Astellas Pharma Inc & Anr. v.Lucius Pharmaceutical Lucius Pharmaceuticals Lao Co Ltd & Ors.
Astellas Pharma Inc and its associates filed a suit seeking permanent injunction against Lucius Pharmaceutical for infringing their Indian Patent No. 292990, which covers the new chemical entity GILTERITINIB. The court examined the prima facie case and balance of convenience before granting an ad interim ex-parte injunction. This order restrained the defendants from manufacturing, selling, or distributing any product infringing the patent, including under the brand name LUCIGIL.
Novartis Ag & Anr v.Intas Pharmaceuticals Limited
The plaintiffs filed a suit seeking a permanent injunction and damages for the infringement of their registered Indian patent (No. 283133) related to Ribociclib. The court subsequently heard various interlocutory applications, including those regarding discovery, exemption from mediation, and an application for interim stay.
Celagenex Research India Pvt Ltd v.Pharmak & Anr.
The plaintiff filed a suit seeking permanent injunction against the defendants for infringing its suit patents. The court examined the composition of the impugned products and found that they used exactly the same salt compositions as the plaintiffs' patented formulations. Consequently, the court granted an ex parte ad-interim injunction.
Cipla Limited v.Union Of India & Ors.
The Delhi High Court issued an order in the dispute between Cipla Limited and the Union of India regarding a trademark application. Recognizing issues with traceability of previous notices, the court allowed Cipla to proceed by granting permission to file applications for the restoration and renewal of Trademark Application No. 1694972 within two weeks. The petitioner was also directed to complete necessary procedural filings within four weeks, effectively allowing the matter to move forward.
Novo Nordisk As v.Dr. Reddys Laboratories Limited & Anr.
Novo Nordisk filed a commercial suit against Dr. Reddys Laboratories Limited regarding the manufacture and sale of an 'impugned drug'. The court addressed various interlocutory applications related to filing documents and pre-institution mediation. In relation to the main suit, the defendants stated they had a license to manufacture but not sell in India, while the plaintiff argued that export of infringing products also constitutes infringement.
Zeria Pharmaceutical Co. Ltd v.The Controller Of Patents
Zeria Pharmaceutical appealed the refusal of its patent application for a novel intermediate compound (formula 5a). The Controller refused the grant, citing lack of novelty and inventive step under Section 2(1)(ja), and falling within the scope of Section 3(d) due to prior art disclosures. The High Court upheld the Controller's decision.
Dr. Reddys Laboratories Limited v.Wockhardt Limited And Anr.
Dr. Reddys Laboratories filed a petition in the Delhi High Court seeking the cancellation of the trademark registration 'PACTYON' held by Wockhardt Limited. The respondents objected to the maintainability of the suit, arguing that the mark was registered in Mumbai. The court accepted notice and set procedural timelines for filing replies and rejoinders, indicating that the matter will proceed through standard litigation steps.
Sun Pharmaceutical Industries Ltd. v.Oziel Pharmaceuticals P. Ltd. & Anr.
The Delhi High Court allowed a joint application for a consent decree in the dispute between Sun Pharmaceutical Industries Ltd. and Oziel Pharmaceuticals P. Ltd. The parties reached an amicable settlement regarding trademark infringement concerning 'PEPFIZ' and 'MINOZ'. Key terms include Defendants recognizing Plaintiff's exclusive rights, agreeing to cease use of deceptively similar marks like 'PEPFIX' and 'MINOZIL', and changing the product name from 'MINOZIL' to 'MINODYL'. The court partially decreed the suit based on these binding settlement terms.
Taiho Pharmaceutical Co Ltd v.The Controller Of Patents
Taiho Pharmaceutical appealed a refusal order by the Controller of Patents regarding its application for a novel piperidine compound. The rejection was based on lack of inventive step and non-patentability under Section 3(d), citing prior art D1. The High Court found that the Controller failed to identify a specific 'known substance' from the Markush structure in D1, making the rejection unsustainable.
Viiv Healthcare Company And Anr v.Dy Controller Of Patents And Designs And Ors.
Viiv Healthcare Company appealed a decision by the Deputy Controller rejecting its patent application (IN 3865/KOLNP/2007) for HIV integrase inhibitors Dolutegravir and Cabotegravir. The appeal challenged the rejection order, citing exceptional delays in the patent process. The court allowed the appeal, setting aside the impugned order.
Vertex Pharmaceuticals Incorporated v.Alivus Life Sciences Limited
The plaintiff filed a suit seeking permanent injunction and damages for infringement of Indian Patent No. IN 282654 related to Ivacaftor. The court initially allowed the exemption from pre-litigation mediation, and subsequently passed an interim order granting ex-parte injunctions against the defendant regarding the use and sale of the patented product.
Dr. Reddys Laboratories Limited v.Novo Nordisk A/S
Dr. Reddys Laboratories Limited filed a petition seeking the revocation of Indian Patent No. IN 262697 before the Delhi High Court. The court issued notice to the respondents (Novo Nordisk A/S) and set timelines for filing replies, while also disposing of several interlocutory applications related to procedural matters.
Viiv Healthcare Company And Anr v.Dy Controller Of Patents And Designs And Ors.
Viiv Healthcare Company appealed a decision by the Deputy Controller rejecting its patent application (IN 3865/KOLNP/2007) for HIV integrase inhibitors, Dolutegravir and Cabotegravir. The court found the rejection order unsustainable due to misinterpretation of previous orders and noted an exceptional delay in the process. Consequently, the appeal was allowed, directing fresh adjudication by another Controller.
Mankind Pharma Limited v.Zhejiang Yige Enterprise Management Group Co Ltd
Mankind Pharma Limited appealed a decision by the Deputy Registrar of Trade Marks regarding an opposition filed against the trademark 'FLORASIS'. The Delhi High Court granted condonation of a 7-day delay in filing the appeal, allowing the matter to proceed. Notice has been issued to all parties, setting the stage for a substantive hearing on the merits of the trademark dispute.
Alkem Laboratories Ltd. v.M/S Martin And Brown Biosciences & Ors.
Alkem Laboratories Ltd. filed a Rectification Petition against M/S Martin And Brown Biosciences & Ors., seeking the removal or cancellation of the trademark registration 'SOMI-MB' (No. 5982177) in Class 5, arguing that it is confusingly similar to their existing mark 'SUMO'. The Delhi High Court issued notice to the respondents and set timelines for filing written synopses and replies, indicating that the matter will proceed through formal litigation.
Glaxo Group Limited v.Qpharm Health Care Limited And Anr
The Delhi High Court addressed multiple issues in the ongoing dispute between Glaxo Group Limited and Qpharm Health Care Limited. The court allowed a petition seeking the transfer and consolidation of trademark rectification proceedings against 'BETNOTREAT' into the main infringement suit, recognizing the interconnected nature of the disputes. Furthermore, after hearing arguments regarding trade dress similarity, the parties were referred to mediation, indicating a potential path toward settlement.
Alkem Laboratories Limited v.Dr. Mariya Parvez & Ors.
The Delhi High Court addressed an application by Alkem Laboratories seeking to include a proposed defendant who had posted misleading content targeting its pharmaceutical products, PAN-D and PAN-40. Although the plaintiff initially sought to extend existing injunctions against this individual, the court noted that the impugned video had already been taken down. Consequently, the court dismissed the impleadment request but reaffirmed that the proposed defendant remains prohibited from using Alkem's 'PAN' family of marks in any videos, reserving the right for the plaintiff to seek further action if infringement recurs.
Miss Kiara Rawat Through Mrs. Lovely Gusain v.Union Of India & Ors.
The petitioner sought directions from the Delhi High Court regarding the high cost of the drug Zolgensma. The petitioner requested that the Union of India facilitate the issuance of compulsory licenses under the Patents Act, 1970, and also asked for the formation of a committee to raise funds for her treatment.
Vifor (International) Ag v.Controller Of Patents
Vifor (International) Ag appealed an order by the Assistant Controller rejecting its patent application for a pharmaceutical composition used to treat iron deficiency. The appellant argued that the rejection based on lack of novelty and inventive step was flawed, as the prior art cited was irrelevant and the Controller ignored technical data provided.
Suncare Formulations Pvt. Ltd. v.Oreo Healthcare
The plaintiffs, manufacturers of pharmaceutical products under the registered trademark 'HAEMOCAL', sued defendants for using the deceptively similar mark 'HEMOCAL' and copying their unique packaging and labeling. The court found that the marks were deceptively similar and likely to cause confusion among the public.
Takeda Pharmaceutical Co Ltd v.Controller Of Patents And Designs And Ors.
Takeda Pharmaceutical appealed a rejection order by the Deputy Controller of Patents & Designs regarding its patent application for Novel Protein Kinase Inhibitors (Brigatinib). The rejection was based on lack of inventive steps and Section 3(d) objections. The High Court allowed the appeal, finding that the respondent failed to consider crucial supplementary data demonstrating Brigatinib's superior selectivity and therapeutic efficacy.
UCB Pharma GMBH v.The Controller of Patents and Designs
UCB Pharma appealed an order refusing to proceed with its patent application for a solid dispersion formulation of Rotigotine. The court found that the Controller had caused inordinate delays and violated statutory timelines, compounded by citing new prior art documents at the hearing without proper notification. Consequently, the impugned order was set aside and the matter was remanded for fresh consideration.
R.Dilip Kumar v.The Registrar of Trademarks, M/s. Sun Pharma Laboratories Limited
The Madras High Court allowed a writ petition filed by R.Dilip Kumar against the Registrar of Trademarks, quashing an order that deemed his trademark application 'PIRALEX' abandoned. The court emphasized that the statutory right of the applicant is at stake and ruled that service of opposition via email alone, without proof of receipt, does not satisfy the legal requirement for initiating the response period. Consequently, both the trademark application and the opposition were restored to the file, allowing the petitioner a fresh opportunity to respond on merits.
Hamdard Laboratories India Medicine Division v.Unani Drugs Manufacturers Association (UDMA)
Hamdard Laboratories India (Medicine Division) appealed against an order dismissing its applications, alleging that UDMA was misleading the public by claiming market dominance and associating Hamdard Food Division products with medicinal claims. The core dispute revolved around the scope of a Family Settlement Deed which divided the HAMDARD Group into Medicine and Food divisions, restricting their respective product lines. The Delhi High Court ultimately dismissed the appeal, noting that the matter fundamentally involved commercial disputes concerning IP rights and required adjudication by a competent Commercial Court.
Mankind Pharma Limited v.Preet Kamal Grewal And Anr.
Mankind Pharma Limited successfully petitioned the Delhi High Court for the removal of a conflicting trademark, 'KINDPAN,' registered by Respondent No. 1 in Class 5. The court ruled that the registration was unsustainable because Mankind is the prior adopter and well-known proprietor of the 'KIND' family of marks in the pharmaceutical sector. By allowing the petition, the High Court reinforced the principle that established goodwill and extensive use grant heightened protection to a trademark owner against confusingly similar registrations.
Psychotropic India Limited v.Meridian Medicare Ltd And Anr.
The Delhi High Court allowed a rectification petition filed by Psychotropic India Limited against Meridian Medicare Ltd. The court found that Respondent No. 1 adopted the mark 'TROMA' with malafide intent, capitalizing on the goodwill established by the petitioner in the pharmaceutical sector. Given the prior use and distinctiveness of the petitioner's marks (TROMANIL, TROMA), the court ruled that the registration held by the respondent was contrary to the Trade Marks Act, leading to its cancellation.
F. Hoffmann-La Roche Ag v.Natco Pharma Limited
F. Hoffmann-La Roche filed a suit alleging infringement of its species patent (IN 334397) for the drug Risdiplam, marketed as EVRYSDI®, by Natco Pharma Limited. The plaintiffs sought an interim injunction to restrain the defendant from manufacturing and selling the API. However, the court found that the defendant had raised a credible challenge regarding the validity of the patent. Considering the public interest in affordable medicine for rare diseases like SMA, the court dismissed the application for interim injunction, though it clarified that damages would be payable if the plaintiffs ultimately succeed in the trial.
Neoculi Pty Ltd v.The Controller Of Patents And Designs and Anr.
Neoculi Pty Ltd appealed a rejection order by the Assistant Controller of Patent and Designs, Kolkata, which rejected its application for an antibacterial pharmaceutical composition. The rejection was based on lack of inventive steps, unpatentability under Section 3(e), and insufficient disclosure. The High Court found the impugned order unsustainable due to non-application of mind and remanded the matter.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.